233 related articles for article (PubMed ID: 21869824)
1. Inhibition and promotion of tumor growth with adeno-associated virus carcinoembryonic antigen vaccine and Toll-like receptor agonists.
Triozzi PL; Aldrich W; Ponnazhagan S
Cancer Gene Ther; 2011 Dec; 18(12):850-8. PubMed ID: 21869824
[TBL] [Abstract][Full Text] [Related]
2. Regulation of the activity of an adeno-associated virus vector cancer vaccine administered with synthetic Toll-like receptor agonists.
Triozzi PL; Aldrich W; Ponnazhagan S
Vaccine; 2010 Nov; 28(50):7837-43. PubMed ID: 20937315
[TBL] [Abstract][Full Text] [Related]
3. Augmentation of antitumor activity of a recombinant adeno-associated virus carcinoembryonic antigen vaccine with plasmid adjuvant.
Ponnazhagan S; Mahendra G; Lima J; Aldrich WA; Jenkins CB; Ren C; Kumar S; Kallman L; Strong TV; Shaw DR; Triozzi PL
Hum Gene Ther; 2004 Sep; 15(9):856-64. PubMed ID: 15353040
[TBL] [Abstract][Full Text] [Related]
4. Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Ishida K; Primus FJ; Yamaue H
Int J Cancer; 2007 Feb; 120(3):585-93. PubMed ID: 17096339
[TBL] [Abstract][Full Text] [Related]
5. Synergistical toll-like receptors activated dendritic cells induce antitumor effects against carcinoembryonic antigen-expressing colon cancer.
Hong X; Dong T; Hu J; Yi T; Li W; Zhang Z; Lin S; Niu W
Int J Colorectal Dis; 2013 Jan; 28(1):25-33. PubMed ID: 22777000
[TBL] [Abstract][Full Text] [Related]
6. TLR9-Activating CpG-B ODN but Not TLR7 Agonists Triggers Antibody Formation to Factor IX in Muscle Gene Transfer.
Butterfield JSS; Biswas M; Shirley JL; Kumar SRP; Sherman A; Terhorst C; Ling C; Herzog RW
Hum Gene Ther Methods; 2019 Jun; 30(3):81-92. PubMed ID: 31140323
[TBL] [Abstract][Full Text] [Related]
7. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
8. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus.
Kass E; Schlom J; Thompson J; Guadagni F; Graziano P; Greiner JW
Cancer Res; 1999 Feb; 59(3):676-83. PubMed ID: 9973217
[TBL] [Abstract][Full Text] [Related]
9. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists.
Rajagopal D; Paturel C; Morel Y; Uematsu S; Akira S; Diebold SS
Blood; 2010 Mar; 115(10):1949-57. PubMed ID: 20065291
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of indoleamine 2,3-dioxygenase activity enhances the anti-tumour effects of a Toll-like receptor 7 agonist in an established cancer model.
Ito H; Ando T; Arioka Y; Saito K; Seishima M
Immunology; 2015 Apr; 144(4):621-30. PubMed ID: 25322876
[TBL] [Abstract][Full Text] [Related]
11. Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effects.
Osada T; Berglund P; Morse MA; Hubby B; Lewis W; Niedzwiecki D; Yang XY; Hobeika A; Burnett B; Devi GR; Clay TM; Smith J; Kim Lyerly H
Cancer Immunol Immunother; 2012 Nov; 61(11):1941-51. PubMed ID: 22488274
[TBL] [Abstract][Full Text] [Related]
12. Interactions between TLR7 and TLR9 agonists and receptors regulate innate immune responses by astrocytes and microglia.
Butchi NB; Du M; Peterson KE
Glia; 2010 Apr; 58(6):650-64. PubMed ID: 19998480
[TBL] [Abstract][Full Text] [Related]
13. scFv6.C4 DNA vaccine with fragment C of Tetanus toxin increases protective immunity against CEA-expressing tumor.
Zanetti BF; Ferreira CP; de Vasconcelos JRC; Han SW
Gene Ther; 2019 Nov; 26(10-11):441-454. PubMed ID: 30770895
[TBL] [Abstract][Full Text] [Related]
14. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
Aarts WM; Schlom J; Hodge JW
Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537
[TBL] [Abstract][Full Text] [Related]
15. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
16. Toll-like receptor 4, Toll-like receptor 7 and Toll-like receptor 9 agonists enhance immune responses against blood-stage Plasmodium chabaudi infection in BALB/c mice.
Gao W; Sun X; Li D; Sun L; He Y; Wei H; Jin F; Cao Y
Int Immunopharmacol; 2020 Dec; 89(Pt B):107096. PubMed ID: 33091818
[TBL] [Abstract][Full Text] [Related]
17. Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy.
Farsaci B; Higgins JP; Hodge JW
Int J Cancer; 2012 Apr; 130(8):1948-59. PubMed ID: 21633954
[TBL] [Abstract][Full Text] [Related]
18. Signaling through TLR7 enhances the immunosuppressive activity of murine CD4+CD25+ T regulatory cells.
Forward NA; Furlong SJ; Yang Y; Lin TJ; Hoskin DW
J Leukoc Biol; 2010 Jan; 87(1):117-25. PubMed ID: 19843574
[TBL] [Abstract][Full Text] [Related]
19. Adoptive immunotherapy as an in vivo model to explore antitumor mechanisms induced by a recombinant anticancer vaccine.
Abrams SI; Hodge JW; McLaughlin JP; Steinberg SM; Kantor JA; Schlom J
J Immunother; 1997 Jan; 20(1):48-59. PubMed ID: 9101413
[TBL] [Abstract][Full Text] [Related]
20. The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine.
Craft N; Bruhn KW; Nguyen BD; Prins R; Lin JW; Liau LM; Miller JF
J Immunol; 2005 Aug; 175(3):1983-90. PubMed ID: 16034143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
